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Abstract
Obesity is a multi-factorial disorder, which is often associated with many other significant diseases
such as diabetes, hypertension and other cardiovascular diseases, osteoarthritis and certain
cancers. The management of obesity will therefore require a comprehensive range of strategies
focussing on those with existing weight problems and also on those at high risk of developing
obesity. Hence, prevention of obesity during childhood should be considered a priority, as there is
a risk of persistence to adulthood. This article highlights various preventive aspects and treatment
procedures of obesity with special emphasis on the latest research manifolds.
Introduction
Obesity can be described as the "New World Syndrome".
Its prevalence is on continuous rise in all age groups of
many of the developed countries in the world. Statistical
data reveals that the problem of obesity has increased
from 12–20% in men and from 16–25% in women over
the last ten years [1]. Recent studies suggest that nearly
15–20% of the middle aged European population are
obese [2] and that in USA alone it is responsible for as
many as 3,00,000 premature deaths each year [3]. Obese
patients have been associated with increased risk of mor-
bidity and mortality relative to those with ideal body
weight [4]. Even modest weight reduction in the range of
5–10% of the initial body weight is associated with signif-
icant improvements in a wide range of co-morbid condi-
tions [5-9]. Obesity, which was once viewed as the result
of lack of will power, or a lifestyle "choice" – the choice to
overeat and under exercise, is now being considered more
appropriately by the modern world as a chronic disease,
which requires effective strategies for its management.
Obesity, in simple terms, may be defined as a state of
imbalance between calories ingested versus calories
expended which would lead to excessive or abnormal fat
accumulation. Body Mass Index (BMI) is a measure of
weight corrected for height and which reflects the total
body fat and has been the most accepted parameter for
defining over weight [10].
Optimal BMI increases with age. WHO also classified over
weight according to BMI [11]. There is a very good corre-
lation between BMI and the percentage of body fat in large
populations.
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Percent Body fat = 1.2 (BMI) + 0.23 (age) - 10.8 (gender)
- 5.4
Where gender = '1' for men and '0' for women.
It follows from this equation that for a given height and
weight, the percentage of body fat is about 10% higher in
women compared to men. The reason for this could be
that in women, the excess body fat is usually distributed
as subcutaneous fat and is mainly peripheral (thighs, but-
tocks, breasts) where as in men there is a relative excess of
body fat stored in abdominal cavity as abdominal subcu-
taneous fat.
New classifications of over weight may be based on cut-off
points for simple anthropometric measures such as waist
hip ratio, total adiposity and intra-abdominal fatness.
There exists a correlation between increased BMI, mortal-
ity due to allied risks which is depicted in Fig. 1
Aetiology of obesity
Obesity is not a single disorder but a heterogeneous group
of conditions with multiple causes each of which is ulti-
mately expressed as obese phenotype. Obesity involves
complex aetiological links between the genetic, metabolic
and neural frameworks on one hand and behavior, food
habits, physical activity and socio-cultural factors on the
other (Table 1).
Genetic considerations
Although obesity had a genetic component, it is not a sim-
ple genetic disorder. There is an underlying genetic predis-
position to obesity on to which environmental factors are
layered. The discovery of 'ob' gene, which was mapped to
chromosome 7, has led to a renewed interest in under-
standing the patho-biological basis of genetic predisposi-
tion in obesity. The 'ob' gene codes a hormone called
leptin, a 167 amino acid protein and was supposed to be
produced in white and brown adipose tissue and placenta
[12]. The leptin receptors are concentrated in hypothala-
mus and belong to the same class of IL-2 and growth hor-
mone receptors [13]. Any mutation of 'ob' gene leads to
improper coding of leptin, which further results in obesity
[14]. The effects of the 'ob' gene are mediated through
effects on both energy intake and energy expenditure.
Obesity can also be considered as a "complex trait" as
many other genes coding proteins like apolipoprotein B,
Table 1: Some important causes and precautionary measures of 
obesity.
Obesity
Causes Management
Sedentary life style Physical activity
Food availability Diet control
High fat diet Behavioural therapy
Hereditary Medication
Drug induced weight gain Surgery
Correlation between increased BMI and risk of mortality Figure 1
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D, E, β3-adrenergic receptor [15], dopamine D2-receptor,
tumor necrosis factor (TNF), glucocorticoid receptor etc.
are associated with it. So far, 200 genes, gene markers and
chromosomal regions have been associated with human
obesity [16].
Neurobiology
Two neurotransmitters neuropeptide Y (NPY) and serot-
onin (5-HT) are found to play a major role in body weight
regulation. NPY is a 36 amino acid peptide, which is
concentrated mainly in the hypothalamus; a region cru-
cial to regulation of appetite [17] has emerged as a possi-
ble key neurotransmitter candidate for the regulation of
energy homeostasis. Increased NPY activity has been
found in the hypothalamus of obese rodents [18]. NPY
increases food in-take through its interaction with a
unique Y5 subtype of NPY receptor and hence Y5 receptor
antagonists could be effective in the treatment of obesity
[19].
The inhibitory actions of 5-HT on food in-take have been
localized to the hypothalamic para ventricular nucleus
(PVN), the site at which NPY is most active in inducing
feeding behavior [20]. 5-HT induced reduction in food in-
take is mediated by post-synaptic 5-HTIB receptors. The
hypophagic actions of 5-HT may be mediated at least
partly through the NPY pathway. For example, 5-HT
antagonist which stimulates feeding increases NPY con-
centrations in the arcuate and para ventricular nuclei of
the hypothalamus [21]. Similarly, a 5-HT agonist, which
reduces food intake significantly, reduces NPY concentra-
tions in the hypothalamic para ventricular nucleus. Corti-
cotrophin releasing factor (CRF) which also causes weight
loss by reducing appetite and act in opposing to NPY on
the regulation of energy balances. Cholecystokinin
(CCK), a neurotransmitter present in the brain plays a
physiological role as a meal termination (satiety) signal
between the two receptors such as CCKA and CCKB, CCK
acted at CCKA receptors [22]. Hence, CCKA agonist could
also be useful in the treatment of obesity.
Environmental factors
These factors play a critical role in the development of
obesity by unmasking genetic or metabolic susceptibili-
ties. Environmental influences act via an increase in
energy intake or a decrease in energy expenditure with lit-
tle physical activity and hence there is increased likeli-
hood of becoming obese. Sedentary behaviors, notably
television watching, car ownership also contributes to the
risk of obesity. The role of passive over consumption [23],
eating disorders, and preference for high carbohydrate
diet also play an important role in increasing the risk of
obesity. Other food habits like smoking and alcohol con-
sumption lowers body weight and results in higher BMI
respectively.
Psycho-social impact
A number of individual characteristics may place individ-
uals at increased risk of obesity. Restrained eating also
plays a role in aetiology of obesity. Restrained eaters
report more food carvings and binge eating [24]. One of
the characteristic features of dietary restraints is the ten-
dency towards disinhibited eating in particular circum-
stances. Restrained eaters may be more susceptible to the
availability of highly palatable foods, which act as a stim-
ulus for excess food consumption.
Obesity-associated diseases and risk factors
Cardiovascular diseases (CVD)
Hypertension
Coronary heart disease
Cerebrovascular disease
Varicose veins
Deep venous thrombosis
The increased risk of CVD is 2-fold in women of BMI 25–
28.9 kg/m2 and 3.6 fold for BMI in 29 kg/m2 or more. In
males a 10% increase in body weight increases risk of
CVD by 38%, where as 20% weight risk corresponds with
86% increased risk. Blood pressure is increased by 6 mm
systole and 4 mm diastole for a 10% gain in body fat.
Hyper tension is prevalent in obese adults at a rate of 2.9
fold than non-obese population and weight reduction
reduces risk of developing hyper tension [25].
Respiratory diseases
Breathless
Sleep apnoea
Hypoventilation syndrome
There are a number of ways in which obesity affects lung
function [26]. An increased amount of fat in the chest wall
and abdomen limits respiratory excursion reducing lung
volume. As the obesity worsens, so do the apnoeic epi-
sodes resulting in frequent awakening and the resultant
sleep deprivation produces daytime somnolence.
Metabolic disorders
Hyperlipidemia
Diabetes mellitus
Insulin resistance
Menstrual irregularitiesNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/3
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There is a consistent graded relationship between
increased BMI and prevalence of NIDDM and insulin
resistance [27]. Over 10 to 15 million Americans with
type 2 diabetes are obese [28]. A mean weight loss of 7%
weight reduces risk of developing type 2 diabetes by more
than 55% [29]. BMI above 35 kg/m2 increases the risk by
93 fold in women and by 42 fold in men. Obesity is
associated with lipid disorders in which elevated levels of
cholesterol, triglycerides, LDL-cholesterol and low levels
of HDL-cholesterol are observed. For every 1 kg of weight
loss, there is a corresponding reduction by about 1% in
HDL and reduction by 3% of triglycerides. It has been
observed that modest weight loss reduces lipid abnormal-
ities [30] and diabetes mellitus [31].
Gastrointestinal disorders
Fatty liver and cirrhosis
Haemorrhoids
Hernia
Colorectal cancer
Gallstones
Gall bladder disease is the most common gastrointestinal
disorder in obese individuals. Obese women have a 2.7
fold increase in the prevalence of gall bladder disease.
There is an increased risk of gallstones in individuals hav-
ing BMI of 20 kg/m2 or more. The mortality rates of cancer
of the stomach and pancreas were higher in obese
individuals.
Malignancies
Breast cancer
Endometrial Cancer
Prostrate Cancer
Cervical Cancer
Obese women have higher incidence of endometrial,
ovarian, cervical and postmenopausal breast cancer, while
obese men have incidents of prostrate cancer.
However, it remains to be confirmed whether these malig-
nancies occur as a result of hormonal changes associated
with obesity or due to specific dietary pattern.
Miscellaneous
Pregnancy
Stress
Arthritis and bone mass
Stress is associated with the consumption of high fat foods
and leads to weight gain. Obesity is also associated with
osteoarthritis of hip and knee although in some cases,
mechanical stress associated with obesity leads to osteoar-
thritis [32]. Obese women have a higher risk of obstetric
complication and have increased risk of caesarean deliv-
ery due to variety of foetal size. Recently, an increased risk
of neural tube defects especially spinabifida has been
reported in women with BMI greater than 29 kg/m2.
Prevention of obesity
Obesity is a serious, chronic medical condition, which is
associated with a wide range of debilitating and life threat-
ening conditions. The fact that obesity prevalence contin-
ues to increase at an alarming rate in almost all regions of
the world is of major concern. Hence, an effective control
of obesity requires the development of coherent strategies
that tackle the main issues related to preventing:
i) The development of over weight in normal weight
individuals
ii) The progression of over weight to obesity in those who
are already over weight
iii) Weight regain in those who have been over weight or
obese in the past but who have since lost weight and
iv) Further worsening of a condition already established.
The prevention of obesity involves action at several levels
i) Primary ii) Secondary iii) Tertiary [33]. Objective of pri-
mary prevention is to decrease the number of new cases,
secondary prevention is to lower the rate of established
cases in the community and tertiary prevention is to stabi-
lize or reduce the amount of disability associated with the
disorder. When the attention is focused on the multi-fac-
torial condition such as coronary heart disease (CHD),
primary prevention of this involves national programmes
to control blood cholesterol levels and secondary preven-
tion deals with reducing CHD risk in those with existing
elevated blood cholesterol levels while tertiary action
would be associated with preventing re-infarction in those
who had a previous heart attack. However, this classifica-
tion system for prevention of obesity results in a great deal
of ambiguity and confusion. To avoid this, the US insti-
tute of medicine [34] has proposed alternative classifica-
tion of system. The new system separates prevention
efforts into 3 levels. Universal (or) public health measures
(directed at every one in the population), selective (for a
sub-group who may have an above average risk of devel-
oping obesity) and indicated (targeted at high risk indi-
viduals who may have a detectable amount of excessNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/3
Page 5 of 8
(page number not for citation purposes)
weight which fore-shadows obesity). However, preventive
measures for any disorder may not be helpful in all cases
hence, proper management strategies can be integrated
along with prevention programmes.
Management of obesity
Management include both weight control or reducing
excess body weight and maintaining that weight loss, as
well as, initiating other measures to control associated risk
factors. Periodic evaluation for obesity should be done by
the measurement of BMI, measurement of waist circum-
ference etc., to assess risk factors. Based on the evaluation,
appropriate treatment can be suggested. Treatment may
consist of modification of diet, increased physical activity,
behavioral therapy, and in certain circumstances weight
loss medication and surgery.
Dietary therapy
Restrictions of calories represent the first line therapy in
all cases except in cases with pregnancy, lactation, termi-
nal illness, anorexia nervosa, cholelithiasis and oste-
oporosis. Low calorie diets (LCD), which provide 100–
1500 kcal/day, resulted in weight loss of 8% of baseline
body weight over six months but on long run most of the
lost weight is regained [35].
Very low calories diets (VLCD), which provide 300–800
kcal/day, can be useful in severely obese patients under
strict medical supervision. They are found to produce 13%
weight loss over six months, i.e. they produce greater
initial weight loss than LCDs, however, the long-term (>1
year) weight loss by VLCD's is not found superior to that
of the LCDs.
Meal replacement programmes and formula diets can be
used as an effective tool in weight management [36].
Optifast, Medifast are available through physians or hos-
pitals as part of packaged weight-reduction programmes.
These products appear to be safe, but maintenance of
weight loss over the long term is difficult.
Other over the counter (OTC) variations to formula diets
includes Slimfast and Ultra slimfast. The consumer is
instructed to drink the formulations and use it to replace
one or two meals.
Fat substitutes like Olestra (Olean), which is a non-digest-
ible, non-caloric fat, can be used in food preparations
taken by obese patients.
It has been observed that calorie restriction alone has
remarkable effects compared to exercise alone [37-39]. A
loss of 5% initial weight achieved with diet and exercise is
associated with significant improvement in glycylated
haemoglobin AIC and that diet control can be useful to
treat co morbidities of obesity such as diabetes [40].
Physical activity
All individuals can benefit from regular exercise [41].
Physical activity, which increases energy expenditure, has
a positive role in reducing fat storage and adjusting energy
balance in obese patients. Various exercises preceded and
followed by short warm up and cool down sessions help
to decrease abdominal fat, prevent loss of muscle mass.
Studies revealed that patients who exercise regularly had
increased cardio vascular fitness [42,43] along with better-
ment in their mental and emotional status. Hence a min-
imum of 30 minutes exercise is recommended for people
of all ages [44] as part of comprehensive weight loss
therapy.
Behaviour therapy
Behaviour therapy is a useful adjunct when incorporated
into treatment for weight loss and weight maintenance.
Patients need to be trained in gaining self-control of their
eating habits. Behaviour modification programmes which
seek to eliminate improper eating behaviours (eating
while watching TV, eating too rapidly, eating when not
hungry etc.,) include individual or group counseling of
patients.
Self-help groups (weight watchers, Nutri-System) use a
program of diet, education and self-monitoring like main-
tenance of logbook, keeping an account of food intake etc
are beneficial.
Pharmacotherapy
Drug treatment is advised only for subjects with BMI > 27
and with associated risk factors or with a BMI > 30 [45]
and thus at medical risk because of their obesity. It should
not be used for "cosmetic" weight loss. Weight loss medi-
cations should be used only as an adjunct to dietary and
exercise regimes coupled with a program of behavioural
treatment and nutritional counseling.
Pharmacological approaches in obesity treatment
Most available weight loss medications are "appetite–sup-
pressant" medications. The initial drugs used for appetite
suppression were amphetamine [46], metamphetamine
and phenmetrazine (Preludin) and are no longer used in
treatment of obesity because of their high potential for
abuse.
Inhibitors of 5-hyroxytryptamine (5-HT) reuptake, fenflu-
ramine and dexfenfluramine were licensed for obesity but
proved to cause pulmonary hyper tension and increased
valvular heart disease [47] and have been withdrawn from
the market. Drugs like phendimetrazine (Plegine),Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/3
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diethylpropion (Tenuate), phentermine (Lonamin) etc.,
are being marketed but have been classified as controlled
substances and are recommended for short-term use only.
The newest agents available for weight loss are sibu-
tramine (Meredia) and orlistat (Xenical). They are the
only weight loss medications approved by the US Food
and Drug Administration (FDA) for long-term use [48] in
significantly obese patients, although their safety and
effectiveness have not been established for use beyond
one year.
Sibutramine is the serotonin and norepinephrine re-
uptake inhibitor, which induces decreased food intake
and increased thermogensis [49-52]. In clinical trials, sib-
utramine showed a statistical improvement in amount of
weight lost versus placebo [53]. It limits decline of meta-
bolic rate that typically accompanies weight loss [54].
However, this agent is contraindicated in-patient with
known seizure disorders, high blood pressure, congestive
heart failure (CHF) a history of myocardial infraction and
arrhythmias.
Orlistat is a potent and irreversible inhibitor of gastric,
pancreatic lipases. It blocks the digestion of approxi-
mately 30% of the ingested dietary triglycerides. Studies
proved that it produces 5% more weight loss than in con-
trol groups [55]. It is now available on prescription as
Xenical® (Orlistat-120 mg). The most commonly reported
side effects include oily stools, soft stool [56], and
increased defecation and decreased absorption of fat-sol-
uble vitamins (A, D, E and K). Hence, patient may be rec-
ommended intake of fat-soluble vitamins [57] along with
it. When used in conjugation with diet it was found to
improve glycemic control and cardiovascular disorders
[58,59].
In general, monotherapy in obese patients produced sub-
optimal weight loss [60] but the use of more than one
weight loss medication at a time (combined drug therapy)
is not approved [61] and hence such an off-label use of
combinations of drugs for weight loss is not recom-
mended except as part of a research study.
Drugs under development
There has been a wide search for effective drugs for the
treatment of obesity. Some of the promising drug devel-
opment research areas are mentioned below.
Amylin is a peptide secreted with insulin in response to
food intake that shares many other properties with estab-
lished adiposity signals like insulin and leptin. Its circulat-
ing levels can be correlated with body fat. Preclinical
studies have shown that amylin complements the effects
of insulin in mealtime glucose regulation via several
effects, which include a suppression of post meal gluca-
gon secretion, a decrease in gastric emptying, and a
decrease in food intake [62]. The drug pramlintide, a syn-
thetic analogue of amylin is currently in phase III trials.
11β-hydroxysteroid dehydrogenase type-1 (11β-HSD-1)
is an enzyme that increases cortisol levels in adipocytes.
Studies on mice lacking gene for 11β-HSD-1 suggest that
they are resistant to diet induced obesity [63]. An 11β-
HSD-1 inhibitor being developed by Biovitrum is cur-
rently in clinical testing.
Stimulation of β3 adrenoreceptors (β3-ARs) by selective
agonists improves insulin action and stimulates energy
metabolism. In animals, chronic β3-AR agonist treatment
causes body weight reduction, which is almost entirely
due to decrease in body fat [64]. At least a dozen pharma-
ceutical companies are in the process of developing β3-AR
drugs, some of which are already in human testing.
AD9677 a β-adrenoceptor agonist is in phase II trails.
The botanical P57 is an extract of steroidal glycosides
derived from South African Cactus. The potent appetite
suppression may occur via the melanocortin-4 (MCR-4)
saponins from the Platycodi radix and  Salacia reticulata
have been shown to inhibit pancreatic lipase, producing
weight loss and reduction of fatty liver in laboratory ani-
mals [65]. Currently, P57 is in Phase II testing and Table
Table 2: List of some important drugs under clinical trials for weight reduction.
Drugs in phase II trials Drugs in phase III trials
Bupropion (dopamine reuptake inhibitor) Mazindol (adrenergic agonist)
Linitript (cholecystokinin A antagonist) Sertraline (selective serotonin uptake inhibitor)
Pegylated leptin Posatirelin (thyrotrphin-releasing hormone analogue)
Dipeptidyl peptidase IV inhibitors Cannabinoid antagonists
Human growth hormone factor AOD9604 Lipase inhibitor, ATL-962
PhytostanolNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/3
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2 summarizes some other important drugs union are
under clinical trials for the treatment of obesity.
Surgery
Apart from drug treatment, surgery is also indicated when
BMI is exceedingly high (>40 kg/m2 or >30 kg/m2 with
obesity-related medical co-morbidities) and when other
treatment modalities have failed [66]. The most popular
surgical procedures used for treatment of severe obesities
involve gastric portioning or gastroplasty and gastric by-
pass. The gastroplasty procedures create a small gastric
pouch, which is drained through a narrow calibrated
stoma [67,68]. The intake of solids is therefore
considerably limited. Gastric by-pass surgery creates a
larger pouch emptied by an anastomosis directly into the
jejunum, bypassing the duodenum. It is considered now
as the most effective and safe surgery for morbid obesity
[69,70]. This technique induces weight loss by combining
restricted intake and a moderate degree of malabsorbtion
[71]. Initial loss of weight is greater after this procedure
than following gastroplasty [72].
Gastric and nutritional complications [73] may be serious
implications of the surgery. Nutritional deficiencies and
intractable vomiting are frequently associated with sur-
gery. Surgical treatments for obesity resolve most co-mor-
bidities of severe obesity such as hypertension [74,75],
serum lipid levels [76] and diabetes mellitus [77,78].
Conclusion
Obesity is not a social condition but is a rampant disease.
Obesity cannot be overviewed as just a matter of overeat-
ing and lack of will power but must be considered as a
major genetic aetiology modified by environment and
should be treated vigorously in the same manner that we
now apply to other diseases. A better understanding of the
aetiological determinants in individual subjects will pro-
vide a basis for more rational intervention to prevent this
recalcitrant public health problem. With the increasing
awareness and ongoing research in this area there is a con-
siderable reason for optimism that the next coming years
will bring better treatment for the obese.
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